Director of Non-viral Delivery

OPPORTUNITY
As Director of Non-viral Delivery, you will be responsible for leading the research and early development activities for non-viral delivery technologies at Mammoth. In this role, you and your team will be responsible for the integration of Mammoth’s proprietary CRISPR nucleases with various non-viral delivery technologies. In addition, you will be responsible for in-house research-scale production and quality control of test articles to support Mammoth’s ex vivo and in vivo studies. 

KEY RESPONSIBILITIES

• Establish and operate in-house LNP production
• Optimize LNP formulations 
• Create and manage budgets
• Evaluate non-viral delivery technologies with collaborators
• Work with the team to define and communicate Mammoth’s gene delivery strategy
• Set up rigorous QC process for test articles
• Hire and mentor additions to the Delivery Team 

REQUIRED QUALIFICATIONS

• Ph.D. in a relevant field, other educational experience considered with additional industry experience
• 8 years of biotechnology experience
• 6 years experience in non-viral delivery

PREFERRED QUALIFICATIONS

• Knowledge of quality systems and GMP
• Experience with DOE optimization of lipid formulations
• Experience managing cross-functional stakeholders up to the executive level
• Previous experience managing external research collaborations and CROs

BENEFITS

• Company-paid health/vision/dental benefits
• Unlimited vacation and generous sick time
• Company-sponsored meals and snacks
• Wellness, caregiver, and ergonomics benefits
• 401(k) with company matching

Mammoth Biosciences is harnessing the diversity of life to power the next generation of CRISPR products. Through the discovery and engineering of novel CRISPR systems, the company is enabling the full potential of its platform to read and write the code of life. Mammoth aims to develop permanent genetic cures through best-in-class in vivo and ex vivo therapies and to democratize disease detection with on-demand diagnostics. Mammoth can provide enhanced diagnostics and genome editing for life science research, healthcare, agriculture, biodefense and more. Based in the San Francisco Bay Area, Mammoth Biosciences is co-founded by CRISPR pioneer and Nobel Laureate Jennifer Doudna and Trevor Martin, Janice Chen, and Lucas Harrington. The firm is backed by top institutional investors including Redmile Group, Foresite Capital, Senator Investment Group, Sixth Street, Decheng, Mayfield, NFX, and 8VC, along with leading individual investors including Brook Byers, Tim Cook, and Jeff Huber.

TEAM
Our small-size proteins, such as Cas14 and CasPhi, are poised to transform disease treatment enabling novel editing approaches and delivery options that are difficult to achieve or not even possible with previously described CRISPR-Cas systems. Our teams are responsible for discovering and engineering novel CRISPR systems, and translating our unique CRISPR technology into therapeutic treatments with the ultimate goal of cures for indications with high medical need.

It is our policy and intent to provide equal opportunity to all persons without regard to race, color, religion, political affiliation, sex/gender (including gender expression/identity, pregnancy, childbirth, and related medical conditions), marital status, registered domestic partner status, sexual orientation, age, ancestry, national origin, veteran status, disability, medical condition, genetic characteristics, and/or any other basis protected by law. This policy covers all facets of employment including, but not limited to: recruitment, selection, placement, promotions, transfers, demotions, terminations, training, and compensation.